Surgery Partners Files 8-K on Financial Condition

TL;DR

**SGRY filed an 8-K on financial results, signaling upcoming performance details.**

AI Summary

Surgery Partners, Inc. filed an 8-K on January 8, 2024, to report an event under Item 2.02, "Results of Operations and Financial Condition." This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. While specific financial figures are not detailed in this excerpt, the filing itself signals that such information will be made public, impacting how investors perceive the stock's value.

Why It Matters

This filing signals that Surgery Partners, Inc. is updating the market on its financial performance, which can directly influence investor confidence and stock price. Investors need to review the full details of the Item 2.02 disclosure to assess the company's operational health.

Risk Assessment

Risk Level: medium — The filing itself doesn't contain specific financial data, so the risk depends entirely on the undisclosed results, which could be positive or negative.

Analyst Insight

A smart investor would await the full disclosure of the 'Results of Operations and Financial Condition' under Item 2.02 to make informed decisions, as this filing merely signals the upcoming release of such critical financial data.

Key Numbers

• January 8, 2024 — Date of Report (The date the earliest event reported in the 8-K occurred.)
• 001-37576 — Commission File Number (Unique identifier for Surgery Partners, Inc. with the SEC.)
• $0.01 — par value per share (The nominal value of Surgery Partners, Inc. Common Stock.)

Key Players & Entities

• Surgery Partners, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Surgery Partners, Inc.
• 001-37576 (dollar_amount) — Commission File Number
• 47-3620923 (dollar_amount) — IRS Employer Identification No.
• 340 Seven Springs Way, Suite 600 Brentwood, Tennessee 37027 (company) — Principal Executive Offices address
• 615-234-5900 (dollar_amount) — Registrant's Telephone Number
• SGRY (company) — Trading Symbol for Common Stock
• The Nasdaq Global Select Market (company) — exchange where Common Stock is registered

Forward-Looking Statements

• Surgery Partners, Inc. will release specific financial results related to its operations and financial condition soon. (Surgery Partners, Inc.) — high confidence, target: Q1 2024
• The market will react to the specific financial details once they are fully disclosed. (SGRY stock price) — medium confidence, target: within 1 week of full disclosure

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share SGRY The Nasdaq Global Select
• $436 million — ng its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue gu
• $440 million — sted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approx
• $2.75 billion — 2023 Revenue guidance of approximately $2.75 billion. This information is included in a Corp
• $495 million — 2024 Adjusted EBITDA to be greater than $495 million. The guidance for the fiscal year ende

Filing Documents

• sgry-20240108.htm (8-K) — 25KB
• 0001638833-24-000006.txt ( ) — 149KB
• sgry-20240108.xsd (EX-101.SCH) — 2KB
• sgry-20240108_lab.xml (EX-101.LAB) — 23KB
• sgry-20240108_pre.xml (EX-101.PRE) — 12KB
• sgry-20240108_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Members of management of Surgery Partners, Inc. (the "Company"), will be meeting with investors on January 8, 2024, as part of the 42nd Annual J.P. Morgan Healthcare Conference, including a presentation at 5:15 p.m. ET. Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion. This information is included in a Corporate Presentation that may be used for these meetings. The Corporate Presentation is available on the Company's website at http://ir.surgerypartners.com/events-and-presentations/presentations. In addition, the Company projects 2024 Adjusted EBITDA to be greater than $495 million. The guidance for the fiscal year ended December 31, 2023 is based on results of the Company through November 2023 and is subject to quarter- and year-end adjustments in connection with the completion of customary financial closing procedures, including management's review and finalization of the results for the full year 2023 and to audit procedures by the Company's independent registered public accounting firm, which have not yet been performed. These customary closing procedures, along with December results, could cause actual results to differ materially from management's guidance. Please also refer to Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, and discussed from time to time in the Company's reports filed with the Securities and Exchange Commission. You are cautioned not to rely on management's guidance being achieved when making an investment decision in the Company's securities. Adjusted EBITDA is a financial measure that has not been prepared in accordance with generally accepted accounting prin

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SURGERY PARTNERS, INC. Date: January 8, 2024 By: /s/ David T. Doherty David T. Doherty Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR